Public Workshop

The Food and Drug Administration (FDA) is announcing the following public workshop titled “Patient and Medical Professional Perspectives on the Return of Genetic Test Results.” The purpose of this workshop is to understand patient and provider perspectives on receiving genetic test results. The topic(s) to be discussed will focus on better defining the specific information…

FDA Voice: Progress and Collaboration on Clinical Trials

By: Barbara D. Buch, M.D. There are few responsibilities at FDA more important than reviewing the design and outcomes of clinical trials. Understanding the science behind the trials — and the individuals included in them — helps us to ensure that the medical products we approve are safe and effective. Last year, FDA took important…

CDRH 2014-2015 Strategic Priorities Accomplishments

%PDF-1.5% 283 0 objendobj 310 0 obj/Filter/FlateDecode/ID[]/Index[283 59]/Info 282 0 R/Length 130/Prev 112299/Root 284 0 R/Size 342/Type/XRef/W[1 3 1]stream hbbd“`b“6A$=f’ɏ QD,`R,RfI0l`5`A$WX DsH+`8#dT|

CDRH 2016-2017 Strategic Priorities

%PDF-1.5% 596 0 objendobj 612 0 obj/Filter/FlateDecode/ID[]/Index[596 41]/Info 595 0 R/Length 89/Prev 253981/Root 597 0 R/Size 637/Type/XRef/W[1 2 1]stream hbbd“b`k@k$r$$D b M ac f`bdzd1#N/

Public Workshop – Next Generation Sequencing

The Food and Drug Administration (FDA) is announcing the following public workshop entitled “Next Generation Sequencing-Based Oncology Panels.” The purpose of this workshop is to obtain feedback on analytical and clinical validation approaches for next generation sequencing (NGS)-based oncology panels. Comments and suggestions generated through this workshop will help guide the development of appropriate regulatory…